Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V. Hirayama, Cameron J. Turtle, Erik L. Kimble et al.|Blood Advances|2023Cited by 56
Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Aude G. Chapuis et al.|Blood Advances|2024Cited by 11
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Cameron J. Turtle, Emily C. Liang et al.|Blood Advances|2025Cited by 10
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Roland B. Walter, Sheryl Y.T. Lim et al.|Molecular Therapy Oncology|2024Cited by 9
Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaAlexandre V. Hirayama, Cameron J. Turtle, Salvatore Fiorenza et al.|Blood|2022Cited by 6